Corporate Events

From April 1, 2025 to June 30, 2025, the company has repurchased 35,525,800 shares, representing 2.27% for ¥33,410.75 million. With this, the company has completed the repurchase of 73,992,600 shares, representing 4.69% for ¥71,775.79 million under the buyback announced on November 7, 2024.

Management Briefing

Toray Industries, Inc. provided second quarter-end and year-end dividend guidance of the year ending March 31, 2026. For the second quarter-end, the company expects to pay dividend of JPY 10.00 per share against JPY 9.00 per share a year ago. For the year-end, the company expects to pay dividend of JPY 10.00 per share against JPY 9.00 per share a year ago.

Toray Industries, Inc. announced dividend of JPY 9.00 per share for the year ended March 31, 2025 against JPY 9.00 per share a year ago. Scheduled date to commence dividend payments is June 27, 2025.

Toray Industries, Inc., Annual General Meeting, Jun 26, 2025, at 10:00 Tokyo Standard Time. Location: Tokyo International Forum, (Hall C), 5-1, Marunouchi 3-chome, Chiyoda-ku, Tokyo Tokyo Japan Agenda: To consider the business report and consolidated financial statements for the 144th business year (from April 1, 2024 to March 31, 2025) and reports of the independent auditor and the board of corporate auditors on the relevant consolidated financial statements conducted respectively; to consider report on the non-consolidated financial statements for the 144th business year (from April 1, 2024 to March 31, 2025); to consider appropriation of surplus; to consider election of ten members of the board; to consider election of two corporate auditors; and to consider other matters.

Toray Industries, Inc., Board Meeting, May 14, 2025. Agenda: To review the company's remuneration system for members of the Board and corporate auditors.

Toray Industries, Inc., Q4 2025 Earnings Call, May 14, 2025

From January 1, 2025 to March 31, 2025, the company has repurchased 22,435,500 shares, representing 1.41% for ¥23,113.1 million. With this, the company has completed the repurchase of 38,466,800 shares, representing 2.42% for ¥38,365.03 million under the buyback announced on November 7, 2024.

Toray Industries, Inc. announced that they will report fiscal year 2025 results on May 14, 2025

Toray Industries, Inc. provided consolidated earnings guidance for the fiscal year ending March 31, 2025. For the fiscal year ending March 31, 2025, the company expects revenue of ¥2,590,000 million, core operating income of ¥145,000 million, profit attributable to owners of parent of ¥88,000 million and basic earnings per share of ¥55.14.

Toray Industries, Inc. expected to report Fiscal Year 2025 results on May 14, 2025. This event was calculated by S&P Global (Created on April 30, 2025).

Toray Industries, Inc. announced that the board of directors has resolved to change the Company's representative members of the board at the Board of Directors Meeting held on February 12, 2025, as described below. Kazuhiko Shuto - New titles: Representative Member of the Board Executive Vice President from Current Title: Member of the Board Executive Vice President. Satoru Hagiwara - New titles: Member of the Board Executive Advisor from Current Title: Representative Member of the Board Executive Vice President. Career summary of newly appointed representative member of the board: Kazuhiko Shuto. Date of birth December 31, 1957. Career: April 1980 Joined the Company; April 2014 General Manager, Textiles Division; June 2014 Vice President (Member of the Board); June 2016 Senior Vice President (Member of the Board); June 2017 Retired from Senior Vice President (Member of the Board); June 2020 Senior Vice President; June 2021 Senior Vice President; June 2022 Senior Vice President (Member of the Board); June 2023 Executive Vice President (Member of the Board) (incumbent). Scheduled date of appointment: April 1, 2025.

Bolt Biotherapeutics, Inc. announced that the target of their worldwide co-development collaboration with Toray Industries, Inc. is Caprin-1, a novel cancer target discovered by Toray. The collaborators are developing a Boltbody Immune-Stimulating Antibody Conjugate (ISAC) targeting Caprin-1, which is applicable to multiple solid tumor types. Under the existing Joint Development and License Agreement, Toray supplies its proprietary antibodies targeting Caprin-1, such as the antibody TRK-950, and Bolt contributes proprietary linker-payloads from its Boltbody ISAC platform technology. Bolt plans to co-develop and jointly commercialize the resulting ISAC product candidate with Toray. Caprin-1 is a tumor-specific antigen that is strongly expressed on the cell membrane surface of most solid tumor, with minimal expression on the surface of normal tissues. Caprin-1 has also been shown to contribute to tumor growth and metastases. Toray's asset TRK-950 is a monoclonal antibody targeting Caprin-1 that is in Phase 2 development for Gastric cancer, providing validation for this antigen as a promising ISAC target. The connection between Toray and Bolt relationship dates back to 2002, when Dr. Fumiyoshi Okano, Senior Director of Toray, worked to enhance cancer immunotherapy techniques in Professor Ed Engleman's lab at Stanford University. After returning to Japan, Dr. Okano discovered the novel cancer therapeutic target Caprin-1 and created an anti Caprin-1 monoclonal antibody TRK-950. Toray later decided to collaborate with Bolt in order to maximize the potential of TRK-950 with the Boltbody ISAC technology. In recent years Toray has increasingly focused on "life innovation", hastening improvements in medical technology and disease prevention. The goal is to reduce the burden on medical professionals while helping people live longer, healthier lives. The company have prioritized oncology as one of the important areas for Toray and are working to create therapies that have the potential to significantly improve outcomes for patients. This collaboration is consistent with Toray's mission to achieve a healthy society through development of innovative drugs.

Toray Industries, Inc., Board Meeting, Feb 12, 2025. Agenda: To consider Reason for change; to consider Names and job titles of newly appointed and retiring representative members of the board; to consider Career summary of newly appointed representative member of the board; and to Scheduled date of appointment April 1, 2025.

Toray Industries, Inc. Presents at American Pancreatic Association (APA) 2024 Annual Meeting, Dec-09-2024 . Venue: Maui, Hawaii, United States. Speakers: Toshiaki Abe.

Toray Industries, Inc., Q3 2025 Earnings Call, Feb 12, 2025

Toray Industries, Inc. Presents at BIO Partnering @JPM Week, Jan-13-2025 . Venue: San Francisco Marriott Marquis, San Francisco, California, United States.

From November 7, 2024 to December 31, 2024, the company has repurchased 16,031,300 shares, representing 1% for ¥15,251.93 million. With this, the company has completed the repurchase of 16,031,300 shares, representing 1% for ¥15,251.93 million under the buyback announced on November 7, 2024.

Toray Industries, Inc., Board Meeting, Nov 07, 2024. Agenda: To consider the repurchase of shares.

Toray Industries, Inc. - Special Call

Toray Industries, Inc. announced that they will report Q3, 2025 results on Feb 12, 2025

Toray Industries, Inc. announced dividend for the second quarter of fiscal year ending March 31, 2025. For the second quarter, the company announced to pay dividend of ¥9.00 per share against ¥9.00 per share a year ago. Scheduled date to commence dividend payments: December 2, 2024. Provided dividend guidance for the full year ending March 31, 2025. For the year, the company expects to pay dividend of ¥9.00 per share against ¥9.00 per share a year ago.

Toray Industries, Inc. provided consolidated earnings guidance for the full year ending March 31, 2025. For the full year ending March 31, 2025, the company expects revenue of ¥2,590,000 million, core operating income of ¥145,000 million, profit attributable to owners of parent of ¥88,000 million and basic earnings per share of ¥54.93.

Toray Industries, Inc., ¥ 9.00, Cash Dividend, Mar-28-2025

Toray Industries, Inc. (TSE:3402) announces a share repurchase program. Under the program, the company will repurchase up to 155,000,000 shares, representing 9.67% of its issued share capital, for ¥100,000 million. The purpose of the program is to improve capital efficiency. The program is valid till November 7, 2025. As of September 30, 2024, there are 1,603,001,688 outstanding shares (excluding treasury stock) and 28,479,715 treasury shares.

The Board of Directors of Toray Industries, Inc. has authorized a buyback plan on November 7, 2024.

Toray Industries, Inc. expected to report Q3 2025 results on February 7, 2025. This event was calculated by S&P Global (Created on November 7, 2024).

Toray Industries, Inc., Q2 2025 Earnings Call, Nov 07, 2024

Toray Industries, Inc. announced that they will report Q2, 2025 results on Nov 07, 2024

Toray Industries, Inc. provided consolidated earnings guidance for the full year ending March 31, 2025. For the full year ending March 31, 2025, the company expects revenue of ¥2,620,000 million, core operating income of ¥135,000 million, profit attributable to owners of parent of ¥81,000 million and basic earnings per share of ¥50.56.

Toray Industries, Inc. revised consolidated earnings guidance for the Six months ending September 30, 2024. For the six months period, the company now expects revenue of ¥1,310,000 million, core operating income of ¥70,000 million, profit attributable to owners of parent of ¥46,000 million and basic earnings per share of ¥28.71 as compared to the previous guidance revenue of ¥1,260,000 million, core operating income of ¥60,000 million, profit attributable to owners of parent of ¥39,000 million and basic earnings per share of ¥24.35.